India's top 500 companies are experiencing robust corporate profit growth of 30.8% annually post-Covid, yet private sector capital formation remains disappointingly weak. This disconnect stems from fundamental structural issues.
The Economic Survey 2024-25 noted that while corporate profits soared, hiring and wage growth remained low, and private sector Gross Fixed Capital Formation in machinery rose only 35% in four years. Without revival in demand, profits alone don't incentivize investment.
The rapid exodus of foreign portfolio investors and sharp slowdown in net foreign direct investment significantly influence Indian companies' overseas deployment decisions. FPI equity inflows plunged 99.7% to just ₹427 crore in 2024 compared to ₹1.71 lakh crore in 2023.
This foreign capital retreat reduces domestic liquidity, increases cost of capital for domestic expansion, and creates valuation arbitrage—rich domestic valuations versus cheaper overseas targets. Companies like Sun Pharma, Tata Motors, and Coforge are responding by seeking growth abroad where returns appear more certain.
Government tax cuts and production-linked subsidies are failing to stimulate sufficient private sector investment. The 2019 corporate tax rate cut was intended to encourage domestic investment, but private spending contribution to GDP remains below historical levels. Business heirs are increasingly becoming wealth managers rather than building new businesses ground up. Companies are sitting on cash worth 11% of total assets rather than deploying it in fresh investments. This policy ineffectiveness, combined with weak domestic consumption in urban areas and muted export demand, is prompting companies to seek growth through overseas acquisitions that offer immediate market access and technology capabilities.
From ₹17 in 1991 to ₹90+ in 2025, this consistent 4.5% annual average depreciation creates significant wealth erosion for rupee-only portfolios. The rupee declined 5.5% in 2025 alone, making it Asia's worst-performing currency. This depreciation inflates the cost of servicing India's $682 billion in foreign debt and raises import costs. Indian companies are responding by acquiring foreign currency assets through overseas deals, creating natural hedges against currency risk while accessing richer markets and technological know-how.
Sun Pharma's $11.75 billion Organon acquisition provides immediate leadership in women's health and an established biosimilars platform—capabilities that would take decades to build organically. Tata Motors' $4.4 billion Iveco acquisition delivers zero-emission transport technology and European market access that domestic investments cannot match. Coforge's $2.35 billion Encora purchase brings an AI-native platform and Silicon Valley engineering talent that addresses India's AI capability gaps. These are capability-led investments rather than prestige-driven deals. Transcripts +1
Indian companies prefer all-cash acquisition structures due to regulatory constraints on share swaps and lessons from past dilution. Sun Pharma's all-cash Organon deal avoids the 15% shareholder dilution experienced in the Ranbaxy acquisition. However, this approach creates significant leverage pressures—Sun Pharma's net debt/EBITDA ratio will reach approximately 2.3x post-acquisition. The inability to use shares as acquisition currency places Indian acquirers at a structural disadvantage compared to global peers, resulting in higher leverage profiles and reduced financial flexibility. With 162 Indian companies spending over $18 billion on outbound acquisitions in 2025 (34% increase), balance sheet discipline becomes critical. Transcripts +1
The Tata Steel-Corus acquisition, which became an "albatross" around the company's neck, offers crucial lessons. Tata paid 608 pence per share—34% more than the previous offering—in an emotionally charged bidding war at the peak of the commodity supercycle. The deal suffered from overvaluation, cultural integration failures, and lack of post-acquisition control. Current acquirers are applying these lessons through disciplined valuation frameworks, cultural due diligence, and active integration planning. Sun Pharma's thoughtful integration approach drawing on learnings from Ranbaxy and Taro, and Coforge's retention of key Encora leadership, demonstrate this evolution. Transcripts +1
Free trade agreements with the UK, Europe, and Australia could accelerate outbound M&A while potentially exacerbating domestic capital outflows. The India-UK FTA eliminates tariffs on 99% of Indian tariff lines, while the EU-India agreement provides market access commitments and investment protection standards. These agreements reduce friction for cross-border investments and create regulatory harmonization that makes overseas assets more attractive. Combined with selective caution on domestic investments and global energy shocks, these FTAs may sustain long-term outbound capital flows regardless of domestic policy incentives.
Perhaps most significantly, next-generation corporate scions living and studying abroad are creating sustainable pathways for outbound capital. With 12.54 lakh Indian higher-education students abroad in 2025 and the study abroad market projected to grow from $38 billion to $58 billion by FY2029, a globally oriented business leadership is emerging. These future leaders bring international networks, cultural competence, and comfort with cross-border transactions that transcend short-term policy considerations. This demographic shift suggests that outbound capital deployment may become structurally embedded in Indian business strategy, requiring policymakers to balance legitimate international expansion with domestic investment revitalization.
